Table 1 Expression levels of ER, PgR and HER family members in human breast cancer cell lines tested

From: Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

Cell line

ERa

PgRa

HER1b

HER2b

HER3b

HER4b

KPL-1

79.7±13.3

NDc

1.5

3.0

2.5

1.0

KPL-3C

90.9±18.2

ND

0.8

3.0

2.7

1.3

T47D

32.5±1.0

8480.0±720.0

1.3

3.7

2.0

2.2

KPL-4

ND

ND

1.8

9.5

2.0

1.1

MDA-MB-231

ND

ND

3.0

2.6

0.8

1.1

  1. aFemtomoles mg−1 protein measured by EIA (mean±s.e.).
  2. bExpression ratio in comparison with internal control (β-actin) by multiplex RT–PCR.
  3. cNot detectable.
Back to article page